TwinBeech Capital’s Compass Therapeutics CMPX Stock Holding History

TwinBeech Capital’s Portfolio CMPX Stock Details CMPX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-10,506	Closed	-$34.4K	–	634
2023 Q1	$34.4K	Buy	+10,506	New	+$41.2K	﹤0.01%	575

Other funds holding CMPX

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

TwinBeech Capital's CMPX Position: Q2 2023 in Review

TwinBeech Capital sold out of Compass Therapeutics (CMPX) in Q2 2023, closing a stake of 10,506 shares — an estimated $34.4K sold.

TwinBeech Capital first reported a position in CMPX in Q1 2023 and held it in 1 quarter. The position peaked at $34.4K in Q1 2023. 73 funds tracked by Wall St. Rank hold CMPX as of Q2 2023.

TwinBeech Capital reported no remaining Compass Therapeutics position as of Q2 2023 after selling out during the quarter.
TwinBeech Capital sold 10,506 Compass Therapeutics shares in Q2 2023, an estimated $34.4K.
TwinBeech Capital first reported a position in Compass Therapeutics in Q1 2023 and held it in 1 quarter.
TwinBeech Capital's Compass Therapeutics position peaked at $34.4K in Q1 2023.
73 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2023.

Based on TwinBeech Capital's 13F filing for Q2 2023, filed 14 Aug 2023.